+ Watch ALXA
on My Watchlist
An emerging pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions.
The Alexza excitement is over now that approval in both the US and Europe was met with a trans-Atlantic loud yawn. The commercial potential of Adasuve is highly questionable and the company will almost certainly dilute ahead of launch. As an ER doc, the very idea of a mask inhalation sedative for an agitated patient seems ridiculous to me. Everything else I hear about the specs such as the necessity of patient compliance with the treatment and the duration of the treatment just make it sound worse. I think unless Alexza can come up with a follow up act to Adasuve, they're likely headed to the same fate as Labopharm. Remember Labopharm?
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions